Erythropoietic-stimulating agents: The cancer progression controversy and collateral damage to the blood supply

Transfusion

Volumn 49, Issue 5, 2009, Pages 824-826

  Adamson, John W ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER GROWTH; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG COST; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK CANCER; HUMAN; IMMUNOMODULATION; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; QUALITY OF LIFE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASCULARIZATION;

ANEMIA; HEMATINICS; HUMANS; NEOPLASMS; RISK ASSESSMENT;

EID: 65349175949     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02165.x     Document Type: Editorial

References (17)

1. Abels RI, Larholt KM, Krantz KD, Bryant EC. Recombinant human erythropoietin (r-HuEPO) for the treatment of the anemia of cancer. In : Murphy MJ Jr., editor. Blood cell growth factors: their present and future use in hematology and oncology. Proceedings of the Beijing Symposium. Dayton (OH) : AlphaMed Press 1991. p. 121 41.
2. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2000 95 : 888 95.
3. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004 15 : 979 86.
4. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005 23 : 2606 17.
5. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001 19 : 2865 74.
6. Glaser CM, Millese W, Kornek GV, Lang S, Schüll B, Watzinger F, Selzer E, Lavey RS. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Biol Phys 2001 50 : 705 15.
7. Thews O, Koenig R, Kelleher DK, Kutzner J, Vaupel P. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 1998 78 : 752 6.
8. Silver DF, Piver MS. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol 1999 73 : 280 4.
9. Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001 28 Suppl 8 : 48 53.
10. Henke M, Laszig R, Rube C, Schäfer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003 362 : 1255 60.
11. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E. Maintaining normal hemoglobin level with epoetin alfa in mainly nonanemic patients with breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005 23 : 5960 72.
12. Vekeman F, Bookhart BK, White J, McKenzie RS, Duh MS, Piech CT, Lefebvre P. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion 2009 DOI: 10.1111/j.1537-2995.2009.02072.x
13. Gilmore J, Feinberg BA, Gondesen T, Jackson J, Bookhart BK, McKenzie RS. Hematologic and transfusion outcomes following implementation of the erythropoiesis stimulating agent (ESA) National Coverage Determination (NCD) in Medicare patients receiving chemotherapy. J Clin Oncol 2008 26 : 6548a.
14. Burton T, Larholt K, Apgar E, Pashos C, Bookhart B, Corral M, Tak Piech C, McKenzie RS. Pre- vs. post-national coverage determination (NCD) blood utilization and hemoglobin values among Medicare patients treated with erythropoietic-stimulating agents (ESAs) for chemotherapy-induced anemia (CIA). Blood 2008 112 : 1301a.
15. Bohlius J, Brillant C, Clarke M, Kluge S, Napoli M, Piper M, Rades D, Ray-Coquard I, Schmidlin K, Schumacher M, Schwarzer G, Seidenfeld J, Steensma DP, Trelle S, Untch M, Weingart O, Zwahlen M, Egger M, Engert A. Recombinant human erythropoiesis stimulating agents in cancer patients: individual patient data meta-analysis on behalf of the EPO IPD Meta-analysis Collaborative Group. ASH Late-breaking abstracts. Blood 2008 112 : LBA 6.
16. Aggarwal S. What's fueling the biotech engine - 2007. Nat Biotech 2008 26 : 1227 1233.
17. Usdin S. Regulation. FDA the enforcer. BioCentury 2008 16 : A11 A12.